The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts

Eric J. Bernhard, Gary Kao, Adrienne D. Cox, Said M. Sebti, Andrew Hamilton, Ruth J. Muschel, W. Gillies McKenna

Research output: Contribution to journalArticle

Abstract

Many tumor cells have a greater resistance to ionizing radiation than their normal counterparts, suggesting that the development of drugs that can reduce that radioresistance would potentiate the efficacy of radiation therapy. Because activated H-ras expression has been shown to markedly increase radiation resistance in some transformed cells, the inactivation of H-ras would then be predicted to radiosensitize these tumor cells, while leaving normal cells unaffected. H-ras depends for activity upon farnesylation, which can be blocked by farnesylation inhibitors, including the compound FTI-277. In keeping with this prediction, inhibition of H-ras processing using FTI-277 resulted in higher levels of apoptosis after irradiation and increased radiosensitivity in H-ras-transformed rat embryo cells but did not affect control cells. These experiments suggest that farnesylation inhibitors may prove clinically useful as radiosensitizers of tumors that depend on ras function.

Original languageEnglish (US)
Pages (from-to)1727-1730
Number of pages4
JournalCancer Research
Volume56
Issue number8
StatePublished - Apr 15 1996

Fingerprint

Farnesyltranstransferase
Embryonic Structures
Fibroblasts
Prenylation
Neoplasms
Radiation Tolerance
Ionizing Radiation
FTI 277
Radiotherapy
Radiation
Apoptosis
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bernhard, E. J., Kao, G., Cox, A. D., Sebti, S. M., Hamilton, A., Muschel, R. J., & McKenna, W. G. (1996). The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Research, 56(8), 1727-1730.

The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. / Bernhard, Eric J.; Kao, Gary; Cox, Adrienne D.; Sebti, Said M.; Hamilton, Andrew; Muschel, Ruth J.; McKenna, W. Gillies.

In: Cancer Research, Vol. 56, No. 8, 15.04.1996, p. 1727-1730.

Research output: Contribution to journalArticle

Bernhard, EJ, Kao, G, Cox, AD, Sebti, SM, Hamilton, A, Muschel, RJ & McKenna, WG 1996, 'The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts', Cancer Research, vol. 56, no. 8, pp. 1727-1730.
Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton A, Muschel RJ et al. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Research. 1996 Apr 15;56(8):1727-1730.
Bernhard, Eric J. ; Kao, Gary ; Cox, Adrienne D. ; Sebti, Said M. ; Hamilton, Andrew ; Muschel, Ruth J. ; McKenna, W. Gillies. / The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. In: Cancer Research. 1996 ; Vol. 56, No. 8. pp. 1727-1730.
@article{80cbbed920534b708b3278605ad6cd87,
title = "The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts",
abstract = "Many tumor cells have a greater resistance to ionizing radiation than their normal counterparts, suggesting that the development of drugs that can reduce that radioresistance would potentiate the efficacy of radiation therapy. Because activated H-ras expression has been shown to markedly increase radiation resistance in some transformed cells, the inactivation of H-ras would then be predicted to radiosensitize these tumor cells, while leaving normal cells unaffected. H-ras depends for activity upon farnesylation, which can be blocked by farnesylation inhibitors, including the compound FTI-277. In keeping with this prediction, inhibition of H-ras processing using FTI-277 resulted in higher levels of apoptosis after irradiation and increased radiosensitivity in H-ras-transformed rat embryo cells but did not affect control cells. These experiments suggest that farnesylation inhibitors may prove clinically useful as radiosensitizers of tumors that depend on ras function.",
author = "Bernhard, {Eric J.} and Gary Kao and Cox, {Adrienne D.} and Sebti, {Said M.} and Andrew Hamilton and Muschel, {Ruth J.} and McKenna, {W. Gillies}",
year = "1996",
month = "4",
day = "15",
language = "English (US)",
volume = "56",
pages = "1727--1730",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts

AU - Bernhard, Eric J.

AU - Kao, Gary

AU - Cox, Adrienne D.

AU - Sebti, Said M.

AU - Hamilton, Andrew

AU - Muschel, Ruth J.

AU - McKenna, W. Gillies

PY - 1996/4/15

Y1 - 1996/4/15

N2 - Many tumor cells have a greater resistance to ionizing radiation than their normal counterparts, suggesting that the development of drugs that can reduce that radioresistance would potentiate the efficacy of radiation therapy. Because activated H-ras expression has been shown to markedly increase radiation resistance in some transformed cells, the inactivation of H-ras would then be predicted to radiosensitize these tumor cells, while leaving normal cells unaffected. H-ras depends for activity upon farnesylation, which can be blocked by farnesylation inhibitors, including the compound FTI-277. In keeping with this prediction, inhibition of H-ras processing using FTI-277 resulted in higher levels of apoptosis after irradiation and increased radiosensitivity in H-ras-transformed rat embryo cells but did not affect control cells. These experiments suggest that farnesylation inhibitors may prove clinically useful as radiosensitizers of tumors that depend on ras function.

AB - Many tumor cells have a greater resistance to ionizing radiation than their normal counterparts, suggesting that the development of drugs that can reduce that radioresistance would potentiate the efficacy of radiation therapy. Because activated H-ras expression has been shown to markedly increase radiation resistance in some transformed cells, the inactivation of H-ras would then be predicted to radiosensitize these tumor cells, while leaving normal cells unaffected. H-ras depends for activity upon farnesylation, which can be blocked by farnesylation inhibitors, including the compound FTI-277. In keeping with this prediction, inhibition of H-ras processing using FTI-277 resulted in higher levels of apoptosis after irradiation and increased radiosensitivity in H-ras-transformed rat embryo cells but did not affect control cells. These experiments suggest that farnesylation inhibitors may prove clinically useful as radiosensitizers of tumors that depend on ras function.

UR - http://www.scopus.com/inward/record.url?scp=0029921232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029921232&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 1727

EP - 1730

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 8

ER -